Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT
We analyzed the results of third allogeneic stem cell transplantation (SCT3) using single-unit unrelated cord blood (CB) in seven adult patients with relapsed acute leukemia after second allogeneic stem cell transplantation (SCT2). The median age at SCT 3 was 44 years (range 20–58 years). The patien...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2015-04, Vol.101 (4), p.392-397 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 397 |
|---|---|
| container_issue | 4 |
| container_start_page | 392 |
| container_title | International journal of hematology |
| container_volume | 101 |
| creator | Konuma, Takaaki Kato, Seiko Ooi, Jun Ebihara, Yasuhiro Mochizuki, Shinji Oiwa-Monna, Maki Tojo, Arinobu Takahashi, Satoshi |
| description | We analyzed the results of third allogeneic stem cell transplantation (SCT3) using single-unit unrelated cord blood (CB) in seven adult patients with relapsed acute leukemia after second allogeneic stem cell transplantation (SCT2). The median age at SCT 3 was 44 years (range 20–58 years). The patients had de novo acute myeloid leukemia (AML) (
n
= 4), secondary AML following myelodysplastic syndrome (
n
= 2), and acute lymphoblastic leukemia (
n
= 1). Four patients received myeloablative conditioning, and three received reduced-intensity conditioning. All but one patient had myeloid reconstitution with remission, but five patients relapsed even after SCT3. However, one patient is alive and disease-free 6 years after SCT3, which is the longest remission duration among three allogeneic SCTs she received. Furthermore, actual survival after relapse of SCT 2 was significantly better for patients who received SCT3 compared with institutional control patients who never received SCT3 (
P
|
| doi_str_mv | 10.1007/s12185-015-1755-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1671213406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3646536801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-c12aa34793a921afb6d54ff6c69d54abdb40fc9c4853e33e940cfd012f2304ef3</originalsourceid><addsrcrecordid>eNp1kUGPFCEQhYnRuLOrP8CLIfGyHlqLBpruo5moa7KJB8czoeli7JWGEeiDZ_-4dGY1auIJUnzvFVWPkGcMXjEA9TqzlvWyASYbpqRs1AOyY30nG66UeEh2MLSykYrBBbnM-Q6AKRDqMbloZScl72FHfhy-zGmixvt4xICzpbngQi16T0syIZ-8CcWUOQZ6_Wl_eEnXPIcjXUNCbwpO1MaqH32ME3Ux0a18yrVu7FqQely_4jIbalzBRDPaGP5qVz2fkEfO-IxP788r8vnd28P-prn9-P7D_s1tYyVvS2NZawwXauBmaJlxYzdJ4Vxnu6FezDiNApwdrOglR85xEGDdBKx1LQeBjl-R67PvKcVvK-ailzlvk5qAcc2adaoulAvoKvriH_QurinU320UQM9FryrFzpRNMeeETp_SvJj0XTPQW0L6nJCuCektIb1pnt87r-OC02_Fr0gq0J6BXJ_CEdMfrf_r-hMd05yf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1670083487</pqid></control><display><type>article</type><title>Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Konuma, Takaaki ; Kato, Seiko ; Ooi, Jun ; Ebihara, Yasuhiro ; Mochizuki, Shinji ; Oiwa-Monna, Maki ; Tojo, Arinobu ; Takahashi, Satoshi</creator><creatorcontrib>Konuma, Takaaki ; Kato, Seiko ; Ooi, Jun ; Ebihara, Yasuhiro ; Mochizuki, Shinji ; Oiwa-Monna, Maki ; Tojo, Arinobu ; Takahashi, Satoshi</creatorcontrib><description>We analyzed the results of third allogeneic stem cell transplantation (SCT3) using single-unit unrelated cord blood (CB) in seven adult patients with relapsed acute leukemia after second allogeneic stem cell transplantation (SCT2). The median age at SCT 3 was 44 years (range 20–58 years). The patients had de novo acute myeloid leukemia (AML) (
n
= 4), secondary AML following myelodysplastic syndrome (
n
= 2), and acute lymphoblastic leukemia (
n
= 1). Four patients received myeloablative conditioning, and three received reduced-intensity conditioning. All but one patient had myeloid reconstitution with remission, but five patients relapsed even after SCT3. However, one patient is alive and disease-free 6 years after SCT3, which is the longest remission duration among three allogeneic SCTs she received. Furthermore, actual survival after relapse of SCT 2 was significantly better for patients who received SCT3 compared with institutional control patients who never received SCT3 (
P
< 0.001). These results suggest that the use of CB may allow the opportunity to perform SCT3 in patients who have experienced relapsed leukemia without donors, and SCT3 with CB may offer the chance of durable remission for selected patients with relapsed acute leukemia.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-015-1755-7</identifier><identifier>PMID: 25655380</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Cord Blood Stem Cell Transplantation - methods ; Female ; Hematology ; Humans ; Leukemia, Myeloid, Acute - complications ; Leukemia, Myeloid, Acute - therapy ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Myelodysplastic Syndromes - complications ; Myelodysplastic Syndromes - therapy ; Neoplasm Recurrence, Local - complications ; Neoplasm Recurrence, Local - therapy ; Oncology ; Original Article ; Stem Cell Transplantation - methods ; Survival Analysis ; Transplantation, Homologous ; Young Adult</subject><ispartof>International journal of hematology, 2015-04, Vol.101 (4), p.392-397</ispartof><rights>The Japanese Society of Hematology 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-c12aa34793a921afb6d54ff6c69d54abdb40fc9c4853e33e940cfd012f2304ef3</citedby><cites>FETCH-LOGICAL-c532t-c12aa34793a921afb6d54ff6c69d54abdb40fc9c4853e33e940cfd012f2304ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-015-1755-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-015-1755-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25655380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Konuma, Takaaki</creatorcontrib><creatorcontrib>Kato, Seiko</creatorcontrib><creatorcontrib>Ooi, Jun</creatorcontrib><creatorcontrib>Ebihara, Yasuhiro</creatorcontrib><creatorcontrib>Mochizuki, Shinji</creatorcontrib><creatorcontrib>Oiwa-Monna, Maki</creatorcontrib><creatorcontrib>Tojo, Arinobu</creatorcontrib><creatorcontrib>Takahashi, Satoshi</creatorcontrib><title>Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>We analyzed the results of third allogeneic stem cell transplantation (SCT3) using single-unit unrelated cord blood (CB) in seven adult patients with relapsed acute leukemia after second allogeneic stem cell transplantation (SCT2). The median age at SCT 3 was 44 years (range 20–58 years). The patients had de novo acute myeloid leukemia (AML) (
n
= 4), secondary AML following myelodysplastic syndrome (
n
= 2), and acute lymphoblastic leukemia (
n
= 1). Four patients received myeloablative conditioning, and three received reduced-intensity conditioning. All but one patient had myeloid reconstitution with remission, but five patients relapsed even after SCT3. However, one patient is alive and disease-free 6 years after SCT3, which is the longest remission duration among three allogeneic SCTs she received. Furthermore, actual survival after relapse of SCT 2 was significantly better for patients who received SCT3 compared with institutional control patients who never received SCT3 (
P
< 0.001). These results suggest that the use of CB may allow the opportunity to perform SCT3 in patients who have experienced relapsed leukemia without donors, and SCT3 with CB may offer the chance of durable remission for selected patients with relapsed acute leukemia.</description><subject>Adult</subject><subject>Cord Blood Stem Cell Transplantation - methods</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - complications</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Myelodysplastic Syndromes - complications</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Neoplasm Recurrence, Local - complications</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Stem Cell Transplantation - methods</subject><subject>Survival Analysis</subject><subject>Transplantation, Homologous</subject><subject>Young Adult</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUGPFCEQhYnRuLOrP8CLIfGyHlqLBpruo5moa7KJB8czoeli7JWGEeiDZ_-4dGY1auIJUnzvFVWPkGcMXjEA9TqzlvWyASYbpqRs1AOyY30nG66UeEh2MLSykYrBBbnM-Q6AKRDqMbloZScl72FHfhy-zGmixvt4xICzpbngQi16T0syIZ-8CcWUOQZ6_Wl_eEnXPIcjXUNCbwpO1MaqH32ME3Ux0a18yrVu7FqQely_4jIbalzBRDPaGP5qVz2fkEfO-IxP788r8vnd28P-prn9-P7D_s1tYyVvS2NZawwXauBmaJlxYzdJ4Vxnu6FezDiNApwdrOglR85xEGDdBKx1LQeBjl-R67PvKcVvK-ailzlvk5qAcc2adaoulAvoKvriH_QurinU320UQM9FryrFzpRNMeeETp_SvJj0XTPQW0L6nJCuCektIb1pnt87r-OC02_Fr0gq0J6BXJ_CEdMfrf_r-hMd05yf</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Konuma, Takaaki</creator><creator>Kato, Seiko</creator><creator>Ooi, Jun</creator><creator>Ebihara, Yasuhiro</creator><creator>Mochizuki, Shinji</creator><creator>Oiwa-Monna, Maki</creator><creator>Tojo, Arinobu</creator><creator>Takahashi, Satoshi</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT</title><author>Konuma, Takaaki ; Kato, Seiko ; Ooi, Jun ; Ebihara, Yasuhiro ; Mochizuki, Shinji ; Oiwa-Monna, Maki ; Tojo, Arinobu ; Takahashi, Satoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-c12aa34793a921afb6d54ff6c69d54abdb40fc9c4853e33e940cfd012f2304ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Cord Blood Stem Cell Transplantation - methods</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - complications</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Myelodysplastic Syndromes - complications</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Neoplasm Recurrence, Local - complications</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Stem Cell Transplantation - methods</topic><topic>Survival Analysis</topic><topic>Transplantation, Homologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Konuma, Takaaki</creatorcontrib><creatorcontrib>Kato, Seiko</creatorcontrib><creatorcontrib>Ooi, Jun</creatorcontrib><creatorcontrib>Ebihara, Yasuhiro</creatorcontrib><creatorcontrib>Mochizuki, Shinji</creatorcontrib><creatorcontrib>Oiwa-Monna, Maki</creatorcontrib><creatorcontrib>Tojo, Arinobu</creatorcontrib><creatorcontrib>Takahashi, Satoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Konuma, Takaaki</au><au>Kato, Seiko</au><au>Ooi, Jun</au><au>Ebihara, Yasuhiro</au><au>Mochizuki, Shinji</au><au>Oiwa-Monna, Maki</au><au>Tojo, Arinobu</au><au>Takahashi, Satoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>101</volume><issue>4</issue><spage>392</spage><epage>397</epage><pages>392-397</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>We analyzed the results of third allogeneic stem cell transplantation (SCT3) using single-unit unrelated cord blood (CB) in seven adult patients with relapsed acute leukemia after second allogeneic stem cell transplantation (SCT2). The median age at SCT 3 was 44 years (range 20–58 years). The patients had de novo acute myeloid leukemia (AML) (
n
= 4), secondary AML following myelodysplastic syndrome (
n
= 2), and acute lymphoblastic leukemia (
n
= 1). Four patients received myeloablative conditioning, and three received reduced-intensity conditioning. All but one patient had myeloid reconstitution with remission, but five patients relapsed even after SCT3. However, one patient is alive and disease-free 6 years after SCT3, which is the longest remission duration among three allogeneic SCTs she received. Furthermore, actual survival after relapse of SCT 2 was significantly better for patients who received SCT3 compared with institutional control patients who never received SCT3 (
P
< 0.001). These results suggest that the use of CB may allow the opportunity to perform SCT3 in patients who have experienced relapsed leukemia without donors, and SCT3 with CB may offer the chance of durable remission for selected patients with relapsed acute leukemia.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>25655380</pmid><doi>10.1007/s12185-015-1755-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2015-04, Vol.101 (4), p.392-397 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1671213406 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Cord Blood Stem Cell Transplantation - methods Female Hematology Humans Leukemia, Myeloid, Acute - complications Leukemia, Myeloid, Acute - therapy Male Medicine Medicine & Public Health Middle Aged Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - therapy Neoplasm Recurrence, Local - complications Neoplasm Recurrence, Local - therapy Oncology Original Article Stem Cell Transplantation - methods Survival Analysis Transplantation, Homologous Young Adult |
| title | Third allogeneic stem cell transplantation (SCT) using unrelated cord blood for relapsed acute leukemia after second allogeneic SCT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A40%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Third%20allogeneic%20stem%20cell%20transplantation%20(SCT)%20using%20unrelated%20cord%20blood%20for%20relapsed%20acute%20leukemia%20after%20second%20allogeneic%20SCT&rft.jtitle=International%20journal%20of%20hematology&rft.au=Konuma,%20Takaaki&rft.date=2015-04-01&rft.volume=101&rft.issue=4&rft.spage=392&rft.epage=397&rft.pages=392-397&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-015-1755-7&rft_dat=%3Cproquest_cross%3E3646536801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1670083487&rft_id=info:pmid/25655380&rfr_iscdi=true |